Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Budd-Chiari syndrome: a review by an expert panel.
- H. Janssen, J. García-Pagán, E. Elias, G. Mentha, A. Hadengue, D. Valla
- Medicine
- Journal of hepatology
- 1 March 2003
Harry L.A. Janssen*, Juan-Carlos Garcia-Pagan, Elwyn Elias, Gilles Mentha, Antoine Hadengue, Dominique-Charles Valla, for the European Group for the Study of Vascular Disorders of the Liver… Expand
Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy.
- B. Condat, F. Pessione, +6 authors D. Valla
- Medicine
- Gastroenterology
- 1 February 2001
BACKGROUND & AIMS
The outcome of portal vein thrombosis in relation to associated prothrombotic states has not been evaluated. We assessed current outcome and predictors of bleeding and thrombotic… Expand
Etiology, management, and outcome of the Budd-Chiari syndrome.
- S. Darwish Murad, A. Plessier, +17 authors H. Janssen
- Medicine
- Annals of internal medicine
- 4 August 2009
BACKGROUND
The Budd-Chiari syndrome (BCS) is hepatic venous outflow obstruction. What is known about the syndrome is based on small studies of prevalent cases.
OBJECTIVE
To characterize the causes… Expand
A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years.
- A. de Gottardi, L. Spahr, +11 authors J. Dumortier
- Medicine
- Archives of internal medicine
- 11 June 2007
BACKGROUND
Alcohol relapse can negatively influence the outcome after liver transplantation (LT). The aim of our study was to identify factors that could be associated with the recurrence of harmful… Expand
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.
- R. Moreau, F. Durand, +29 authors J. Cadranel
- Medicine
- Gastroenterology
- 1 April 2002
BACKGROUND & AIMS
Type 1 hepatorenal syndrome (HRS) is a severe complication of cirrhosis associated with a short median survival time (<2 weeks). Although the administration of terlipressin improves… Expand
Expression of NOX1, a superoxide‐generating NADPH oxidase, in colon cancer and inflammatory bowel disease
- I. Szántó, L. Rubbia-Brandt, +6 authors K.-H. Krause
- Medicine
- The Journal of pathology
- 1 October 2005
Reactive oxygen species (ROS) are at the centre of many physiological and pathological processes. NOX1, a ROS‐producing NADPH oxidase, is highly expressed in the colon but its function in colonic… Expand
Non-Alcoholic Fatty Liver Disease in Liver Transplant Recipients: Another Story of “Seed and Soil”
- J. Dumortier, E. Giostra, +7 authors A. Hadengue
- Medicine
- The American Journal of Gastroenterology
- 1 March 2010
OBJECTIVES:Fatty liver disease is a potential long-term complication of liver transplantation (LT). We therefore aimed to determine the prevalence and risk factors of liver steatosis in a large… Expand
Performance of endosonography-guided fine needle aspiration and biopsy in the diagnosis of pancreatic cystic lesions
- J. Frossard, P. Amouyal, +7 authors M. Fabre
- Medicine
- American Journal of Gastroenterology
- 1 July 2003
OBJECTIVE:Preoperative diagnosis of cystic lesions of the pancreas remains difficult despite improvement in imaging modalities and cystic fluid analysis. The aim of our study was to assess the… Expand
Transjugular intrahepatic portosystemic shunts: Comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial
- D. Lebrec, N. Giuily, +7 authors S. Erlinger
- Medicine
- 1 August 1996
Abstract Background/Aims: Transjugular intrahepatic portosystemic shunts reduce portal pressure and can control ascites in patients with cirrhosis. We carried out a controlled study to evaluate this… Expand
Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: An outcome‐oriented decision…
- P. Majno, F. Sarasin, G. Mentha, A. Hadengue
- Medicine
- Hepatology
- 1 April 2000
Two treatments are accepted for patients with solitary hepatocellular carcinoma ≤5 cm in size and with preserved hepatic function: (1) liver resection, which can be performed without delay but has a… Expand